135 related articles for article (PubMed ID: 3103537)
21. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
22. [Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo].
Nakamura H; Yu-Qin W; Miyauchi S; Nishioka N; Tanaka H; Harada N; Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 May; 11(5):1049-55. PubMed ID: 6426401
[TBL] [Abstract][Full Text] [Related]
23. 1-Hexylcarbamoyl-5-fluorouracil is more cytostatic than 5-fluorouracil against human tumors in vitro.
Maehara Y; Kusumoto H; Anai H; Kusumoto T; Hiramoto Y; Sugimachi K
Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1511-5. PubMed ID: 3678315
[TBL] [Abstract][Full Text] [Related]
24. [5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur].
Arima S; Futami K; Shigeta M; Kinashi M; Shimura H
Gan To Kagaku Ryoho; 1986 Aug; 13(8):2618-24. PubMed ID: 3090940
[TBL] [Abstract][Full Text] [Related]
25. Dipyridamole augments the antitumor effects of fluorinated pyrimidines.
Sakaguchi Y; Kusumoto T; Kusumoto H; Maehara Y; Furusawa M; Sugimachi K
Anticancer Res; 1992; 12(1):119-21. PubMed ID: 1567156
[TBL] [Abstract][Full Text] [Related]
26. [Results of the UFT sensitivity test using human urogenital cancers transplanted subcutaneously and under the subrenal capsule of nude mice].
Murahashi I; Honda M; Mukae K; Hosoya Y; Takasaki E
Gan To Kagaku Ryoho; 1988 Feb; 15(2):231-5. PubMed ID: 3124766
[TBL] [Abstract][Full Text] [Related]
27. [5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207].
Takeshita M; Ishikawa H; Seki M; Ikeya T; Miyamoto Y; Izuo M; Tozuka S; Usui R; Kaneko H
Gan No Rinsho; 1985 Oct; 31(13):1697-703. PubMed ID: 3935831
[TBL] [Abstract][Full Text] [Related]
28. [UFT concentration in various tissues from cancer patients].
Kasai Y; Nakanishi Y; Nishi H; Nishindai H; Yoshimoto M; Nakamura T; Hashimoto I; Sawada Y; Mikami J; Bekki E
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2130-8. PubMed ID: 6414381
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of the chemosensitivity test by subrenal capsule assay].
Terashima M; Ikeda K; Satoh M; Ishida K; Yoshida H; Mori S; Inada K; Yoshida M
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):653-8. PubMed ID: 2435246
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of subrenal capsule assay (SRC) for clinical cancers].
Akao S; Iwami N; Oya M; Terada H; Sasaki K; Ishikawa H; Kiumi F
Gan To Kagaku Ryoho; 1996 Apr; 23(5):607-13. PubMed ID: 8678520
[TBL] [Abstract][Full Text] [Related]
31. Thymidylate synthase inhibition as a predictor of tumor sensitivity of fluorinated pyrimidines.
Suzuki M; Sekiguchi I; Tamada T
Asia Oceania J Obstet Gynaecol; 1990 Jun; 16(2):175-80. PubMed ID: 2116122
[TBL] [Abstract][Full Text] [Related]
32. [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT].
Inaba S; Kondo Y; Tsuchiya K; Kawai K; Ogino A; Umeda T; Ueda Y
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2175-80. PubMed ID: 1444483
[TBL] [Abstract][Full Text] [Related]
33. [Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT].
Sinmyo K; Hosoi H; Suwa H; Kitagawa M; Yamaguchi K; Susaki H
Gan To Kagaku Ryoho; 1989 May; 16(5):2051-7. PubMed ID: 2499267
[TBL] [Abstract][Full Text] [Related]
34. [Experimental and clinical study of interactions between fluorinated pyrimidine derivatives and anticoagulants].
Ogawa J; Inoue H; Koide S; Kawada S; Shohtsu A
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2265-71. PubMed ID: 3136697
[TBL] [Abstract][Full Text] [Related]
35. [A study of urinary tegafur, 5-fluorouracil (5-FU) and uracil concentrations in the cases of gastric carcinoma for the confirmation of drug-taking compliance after UFT oral administration].
Ohsawa S; Kondo Y; Shiroto H; Masuko H; Fukushima T; Kataoka A; Ohmori K; Sawaguchi Y; Baba E; Takahashi T
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2189-93. PubMed ID: 1444485
[TBL] [Abstract][Full Text] [Related]
36. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
Yamamoto J; Toide K; Haruno A; Yoshimura Y; Unemi N
Arzneimittelforschung; 1981; 31(8):1268-78. PubMed ID: 6794578
[TBL] [Abstract][Full Text] [Related]
37. [Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT].
Futami K; Arima S; Yoshimura S; Okamoto T; Yamasaki K; Koto T; Yamasaki S; Kawahara K; Ikuno T
Gan To Kagaku Ryoho; 1991 Feb; 18(2):215-20. PubMed ID: 1992915
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
Nio Y; Iguchi C; Kodama H; Itakura M; Hashimoto K; Koike M; Toga T; Maruyama R; Fukushima M
Oncol Rep; 2007 Jan; 17(1):153-9. PubMed ID: 17143493
[TBL] [Abstract][Full Text] [Related]
39. [A six-day subrenal capsule assay for predictive testing of primary human tumors].
Yokoyama E; Irimajiri N; Shirakabe M; Matsumoto M; Haneda J; Kusunoki T; Utsunomiya J
Gan To Kagaku Ryoho; 1988 Jan; 15(1):67-71. PubMed ID: 3337530
[TBL] [Abstract][Full Text] [Related]
40. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
